Marisa Garshick, MD, a board-certified dermatologist and clinical assistant professor, discusses resources and tools that can ...

Certain medications may worsen psoriasis so it is always important to consult your provider before taking a new medicine. Stress can contribute to psoriasis, so stress management is important, as are ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

We recently published a list of The Top 10 Performing Stocks on Wednesday. In this article, we are going to take a look at ...

Arcutis Biotherapeutics (ARQT) announced that Padagis Israel Pharmaceuticals, Padagis, and Padagis have requested a stay to the ongoing patent ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Investigators compared outcomes among patients with psoriasis undergoing apremilast treatment with genital involvement versus those without genital involvement.

New Therapeutic Drug Monitoring Test for Interleukin‐23 Inhibitor SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, ...

Post-hoc analyses of the EFFISAYIL 2 trial revealed improvements in Psoriasis Symptom Scale (PSS), Pain Visual Analog Scale ...